Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Stéphanie B. N. Serre"'
Autor:
Sanne B. Jensen, Jens Bukh, Ulrik Fahnøe, Stéphanie B. N. Serre, Kristian Schønning, Martin Schou Pedersen, Santseharay Ramirez, Judith M. Gottwein, Lubna Ghanem, Qi Tang, Daryl Humes, Long V. Pham
Publikováno v:
Journal of Hepatology. 70:388-397
Background & Aims Protease inhibitors (PIs) are of central importance in the treatment of patients with chronic hepatitis C virus (HCV) infection. HCV NS3 protease (NS3P) position 80 displays polymorphisms associated with resistance to the PI simepre
Autor:
Daryl Humes, Sanne B. Jensen, Jens Bukh, Yi-Ping Li, Stéphanie B. N. Serre, Santseharay Ramirez, Judith M. Gottwein
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:7426-7436
Various protease inhibitors (PIs) currently are becoming available for treatment of hepatitis C virus (HCV). For genotype 1, substitutions at NS3 protease positions 155, 156, and 168 are the main determinants of PI resistance. For other genotypes, si
Autor:
Jean-Michel Pawlotsky, Sanne B. Jensen, Henrik Krarup, Christina Sølund, Daryl Humes, Stéphanie B. N. Serre, Christoph Sarrazin, Santseharay Ramirez, Jonathan Filskov, Judith M. Gottwein, Long V. Pham, Jens Bukh, Anne Finne Pihl, Lubna Ghanem, Julia Dietz, Slim Fourati, Ulrik Fahnøe, Nina Weis, Kristian Schønning, Qi Tang, Martin Schou Pedersen
Publikováno v:
Hepatology (Baltimore, Md.)
Jensen, S B, Fahnøe, U, Pham, L V, Serre, S, Tang, Q, Ghanem, L, Pedersen, M S, Ramirez, S, Humes, D, Pihl, A F, Filskov, J, Sølund, C S, Dietz, J, Fourati, S, Pawlotsky, J-M, Sarrazin, C, Weis, N, Schønning, K, Krarup, H, Bukh, J & Gottwein, J M 2019, ' Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants ', Hepatology, vol. 70, no. 3, pp. 771-787 . https://doi.org/10.1002/hep.30647
Jensen, S B, Fahnøe, U, Pham, L V, Serre, S B N, Tang, Q, Ghanem, L, Pedersen, M S, Ramirez, S, Humes, D, Pihl, A F, Filskov, J, Sølund, C S, Dietz, J, Fourati, S, Pawlotsky, J M, Sarrazin, C, Weis, N, Schønning, K, Krarup, H, Bukh, J & Gottwein, J M 2019, ' Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants ', Hepatology, vol. 70, no. 3, pp. 771-787 . https://doi.org/10.1002/hep.30647
Jensen, S B, Fahnøe, U, Pham, L V, Serre, S, Tang, Q, Ghanem, L, Pedersen, M S, Ramirez, S, Humes, D, Pihl, A F, Filskov, J, Sølund, C S, Dietz, J, Fourati, S, Pawlotsky, J-M, Sarrazin, C, Weis, N, Schønning, K, Krarup, H, Bukh, J & Gottwein, J M 2019, ' Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants ', Hepatology, vol. 70, no. 3, pp. 771-787 . https://doi.org/10.1002/hep.30647
Jensen, S B, Fahnøe, U, Pham, L V, Serre, S B N, Tang, Q, Ghanem, L, Pedersen, M S, Ramirez, S, Humes, D, Pihl, A F, Filskov, J, Sølund, C S, Dietz, J, Fourati, S, Pawlotsky, J M, Sarrazin, C, Weis, N, Schønning, K, Krarup, H, Bukh, J & Gottwein, J M 2019, ' Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants ', Hepatology, vol. 70, no. 3, pp. 771-787 . https://doi.org/10.1002/hep.30647
Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance de
Autor:
Daryl Humes, Henrik Krarup, Jens Bukh, Sanne B. Jensen, Yi-Ping Li, Stéphanie B. N. Serre, Santseharay Ramirez, Judith M. Gottwein, Lubna Ghanem
Publikováno v:
Serre, S B N, Jensen, S B, Ghanem, L, Humes, D G, Ramirez, S, Li, Y-P, Krarup, H, Bukh, J & Gottwein, J M 2016, ' Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants : In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle ', Antimicrobial Agents and Chemotherapy, vol. 60, no. 6, pp. 3563-3578 . https://doi.org/10.1128/AAC.02929-15
Hepatitis C virus (HCV) NS3 protease inhibitors (PIs) are important components of novel HCV therapy regimens. Studies of PI resistance initially focused on genotype 1. Therefore, knowledge about the determinants of PI resistance for the highly preval
Publikováno v:
Serre, S B N, Krarup, H B, Bukh, J & Gottwein, J M 2013, ' Identification of IFN-alpha Induced Envelope Mutations of Hepatitis C Virus In Vitro Associated with Increased Viral Fitness and Interferon Resistance ', Journal of Virology, vol. 87, no. 23, pp. 12776-12793 . https://doi.org/10.1128/JVI.00901-13
Alpha interferon (IFN-α) is an essential component of innate antiviral immunity and of treatment regimens for chronic hepatitis C virus (HCV) infection. Resistance to IFN might be important for HCV persistence and failure of IFN-based therapies. Evi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c3ffb18151527579492acfafa0b059
https://vbn.aau.dk/da/publications/11213240-aae6-41bc-be5c-c322caa75e3b
https://vbn.aau.dk/da/publications/11213240-aae6-41bc-be5c-c322caa75e3b
Autor:
Jens Bukh, Sanne B. Jensen, Lubna Ghanem, Judith M. Gottwein, Yi-Ping Li, Troels K. H. Scheel, Lotte S. Mikkelsen, Stéphanie B. N. Serre
With the development of directly acting antivirals, hepatitis C virus (HCV) therapy entered a new era. However, rapid selection of resistance mutations necessitates combination therapy. To study combination therapy in infectious culture systems, we a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d481c294f80662288fc9cb7b59734681
https://europepmc.org/articles/PMC3591891/
https://europepmc.org/articles/PMC3591891/
Autor:
Jens Bukh, Lubna Ghanem, Sanne B. Jensen, Lotte S. Mikkelsen, Henrik Krarup, Troels K. H. Scheel, Nathalie Uzcategui, Tanja B. Jensen, Judith M. Gottwein, Stéphanie B. N. Serre
Publikováno v:
Gottwein, J M, Jensen, S B, Serre, S B N, Ghanem, L, Scheel, T K H, Jensen, T B, Krarup, H, Uzcategui, N, Mikkelsen, L S & Bukh, J 2013, ' Adapted J6/JFH1-based hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon and a putative NS4A inhibitor ', Antimicrobial Agents and Chemotherapy, vol. 57, no. 12, pp. 6034-6049 . https://doi.org/10.1128/AAC.01176-13
To facilitate studies of hepatitis C virus (HCV) NS4A, we aimed at developing J6/JFH1-based recombinants with genotype 1- to 7-specific NS4A proteins. We developed efficient culture systems expressing NS4A proteins of genotypes (isolates) 1a (H77 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::956fce95e737d1e8e4516a3ed1c7c8b1
https://vbn.aau.dk/da/publications/e9056f93-3446-40a4-8aab-c66ba5ae66f1
https://vbn.aau.dk/da/publications/e9056f93-3446-40a4-8aab-c66ba5ae66f1
Autor:
Tanja B. Jensen, Geert Leroux-Roels, Jacob B. Lademann, Judith M. Gottwein, Philip Meuleman, Troels K. H. Scheel, Christian K. Mathiesen, Jens Bukh, Stéphanie B. N. Serre, Lubna Ghanem
To facilitate genotype-specific high-throughput studies of hepatitis C virus (HCV), we have developed reporter viruses using JFH1-based recombinants expressing core-nonstructural protein 2 (NS2) of genotype 1 to 7 prototype isolates. We introduced en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d82766b613c8688410000b3acc14e322
https://europepmc.org/articles/PMC3165809/
https://europepmc.org/articles/PMC3165809/
Autor:
Sanne B. Jensen, Daryl Humes, Y.-P. Li, Santseharay Ramirez, Judith M. Gottwein, Jens Bukh, Stéphanie B. N. Serre
Publikováno v:
Journal of Hepatology. 60:S529-S530
Publikováno v:
Journal of Hepatology. 58:S472
for HCV genotyping released in 1994, in addition to the highly conserved 5′-UTR and Core regions. Whereas treatment response/resistance was assessed mainly in the Interferon sensitivity determining region (ISDR) region of NS5A. Conclusions: While s